|
1
|
Ferlay J, Soerjomataram I, Ervik M,
Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and
Bray F: Cancer incidence and mortality worldwide: Sources, methods
and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386.
2015. View Article : Google Scholar
|
|
2
|
Schlessinger J: Ligand-induced,
receptor-mediated dimerization and activation of EGF receptor.
Cell. 110:669–672. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Riese DJ II and Stern DF: Specificity
within the EGF family/ErbB receptor family signaling network.
BioEssays. 20:41–48. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yarden Y and Sliwkowski MX: Untangling the
ErbB signalling network. Nat Rev Mol Cell Biol. 2:127–137. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tang J, Liu N and Zhuang S: Role of
epidermal growth factor receptor in acute and chronic kidney
injury. Kidney Int. 83:804–810. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kim MA, Lee HS, Lee HE, Jeon YK, Yang HK
and Kim WH: EGFR in gastric carcinomas: Prognostic significance of
protein overexpression and high gene copy number. Histopathology.
52:738–746. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Langer R, Von Rahden BH, Nahrig J, Von
Weyhern C, Reiter R, Feith M, Stein HJ, Siewert JR, Höfler H and
Sarbia M: Prognostic significance of expression patterns of
c-erbB-2, p53, p16INK4A, p27KIP1, cyclin D1 and epidermal growth
factor receptor in oesophageal adenocarcinoma: A tissue microarray
study. J Clin Pathol. 59:631–634. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lieto E, Ferraraccio F, Orditura M,
Castellano P, Mura AL, Pinto M, Zamboli A, De Vita F and Galizia G:
Expression of vascular endothelial growth factor (VEGF) and
epidermal growth factor receptor (EGFR) is an independent
prognostic indicator of worse outcome in gastric cancer patients.
Ann Surg Oncol. 15:69–79. 2008. View Article : Google Scholar
|
|
9
|
Bang YJ, Van Cutsem E, Feyereislova A,
Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T,
et al ToGA Trial Investigators: Trastuzumab in combination with
chemotherapy versus chemotherapy alone for treatment of
HER2-positive advanced gastric or gastro-oesophageal junction
cancer (ToGA): A phase 3, open-label, randomised controlled trial.
Lancet. 376:687–697. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ryu MH, Yoo C, Kim JG, Ryoo BY, Park YS,
Park SR, Han HS, Chung IJ, Song EK, Lee KH, et al: Multicenter
phase II study of trastuzumab in combination with capecitabine and
oxaliplatin for advanced gastric cancer. Eur J Cancer. 51:482–488.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chua C, Tan IB, Yamada Y, Rha SY, Yong WP,
Ong WS, Tham CK, Ng M, Tai DW, Iwasa S, et al: Phase II study of
trastuzumab in combination with S-1 and cisplatin in the first-line
treatment of human epidermal growth factor receptor HER2-positive
advanced gastric cancer. Cancer Chemother Pharmacol. 76:397–408.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Douillard JY, Siena S, Cassidy J,
Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham
D, Jassem J, et al: Randomized, phase III trial of panitumumab with
infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4)
versus FOLFOX4 alone as first-line treatment in patients with
previously untreated metastatic colorectal cancer: The PRIME study.
J Clin Oncol. 28:4697–4705. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Waddell T, Chau I, Cunningham D, Gonzalez
D, Okines AF, Okines C, Wotherspoon A, Saffery C, Middleton G,
Wadsley J, et al: Epirubicin, oxaliplatin, and capecitabine with or
without panitumumab for patients with previously untreated advanced
oesophagogastric cancer (REAL3): A randomised, open-label phase 3
trial. Lancet Oncol. 14:481–489. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang X, Xu J, Liu H, Yang L, Liang J, Xu
N, Bai Y, Wang J and Shen L: Predictive biomarkers for the efficacy
of cetuximab combined with cisplatin and capecitabine in advanced
gastric or esophagogastric junction adenocarcinoma: A prospective
multi-center phase 2 trial. Med Oncol. 31:2262014. View Article : Google Scholar
|
|
15
|
Lordick F, Kang YK, Chung HC, Salman P, Oh
SC, Bodoky G, Kurteva G, Volovat C, Moiseyenko VM, Gorbunova V, et
al Arbeitsgemeinschaft Internistische Onkologie and EXPAND
Investigators: Capecitabine and cisplatin with or without cetuximab
for patients with previously untreated advanced gastric cancer
(EXPAND): A randomised, open-label phase 3 trial. Lancet Oncol.
14:490–499. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Xu CD: Clinical study of nimotuzumab
combined with chemotherapy in the treatment of late stage gastric
cancer. Asian Pac J Cancer Prev. 15:10273–10276. 2014. View Article : Google Scholar
|
|
17
|
Gupta MK and Qin RY: Mechanism and its
regulation of tumor-induced angiogenesis. World J Gastroenterol.
9:1144–1155. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kim KJ, Li B, Winer J, Armanini M, Gillett
N, Phillips HS and Ferrara N: Inhibition of vascular endothelial
growth factor-induced angiogenesis suppresses tumour growth in
vivo. Nature. 362:841–844. 1993. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ferrara N, Hillan KJ, Gerber HP and
Novotny W: Discovery and development of bevacizumab, an anti-VEGF
antibody for treating cancer. Nat Rev Drug Discov. 3:391–400. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Uronis HE, Bendell JC, Altomare I, Blobe
GC, Hsu SD, Morse MA, Pang H, Zafar SY, Conkling P, Favaro J, et
al: A phase II study of capecitabine, oxaliplatin, and bevacizumab
in the treatment of metastatic esophagogastric adenocarcinomas.
Oncologist. 18:271–272. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ohtsu A, Shah MA, Van Cutsem E, Rha SY,
Sawaki A, Park SR, Lim HY, Yamada Y, Wu J, Langer B, et al:
Bevacizumab in combination with chemotherapy as first-line therapy
in advanced gastric cancer: A randomized, double-blind,
placebo-controlled phase III study. J Clin Oncol. 29:3968–3976.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Van Cutsem E, de Haas S, Kang YK, Ohtsu A,
Tebbutt NC, Ming Xu J, Peng Yong W, Langer B, Delmar P, Scherer SJ,
et al: Bevacizumab in combination with chemotherapy as first-line
therapy in advanced gastric cancer: A biomarker evaluation from the
AVAGAST randomized phase III trial. J Clin Oncol. 30:2119–2127.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Shen L, Li J, Xu J, Pan H, Dai G, Qin S,
Wang L, Wang J, Yang Z, Shu Y, et al: Bevacizumab plus capecitabine
and cisplatin in Chinese patients with inoperable locally advanced
or metastatic gastric or gastroesophageal junction cancer:
Randomized, double-blind, phase III study (AVATAR study). Gastric
Cancer. 18:168–176. 2015. View Article : Google Scholar :
|
|
25
|
Spratlin JL, Cohen RB, Eadens M, Gore L,
Camidge DR, Diab S, Leong S, O'Bryant C, Chow LQ, Serkova NJ, et
al: Phase I pharmacologic and biologic study of ramucirumab
(IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody
targeting the vascular endothelial growth factor receptor-2. J Clin
Oncol. 28:780–787. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Fuchs CS, Tomasek J, Yong CJ, Dumitru F,
Passalacqua R, Goswami C, Safran H, dos Santos LV, Aprile G, Ferry
DR, et al REGARD Trial Investigators: Ramucirumab monotherapy for
previously treated advanced gastric or gastro-oesophageal junction
adenocarcinoma (REGARD): An international, randomised, multicentre,
placebo-controlled, phase 3 trial. Lancet. 383:31–39. 2014.
View Article : Google Scholar
|
|
27
|
Wilke H, Muro K, Van Cutsem E, Oh SC,
Bodoky G, Shimada Y, Hironaka S, Sugimoto N, Lipatov O, Kim TY, et
al RAINBOW Study Group: Ramucirumab plus paclitaxel versus placebo
plus paclitaxel in patients with previously treated advanced
gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): A
double-blind, randomised phase 3 trial. Lancet Oncol. 15:1224–1235.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yoon HH, Bendell JC, Braiteh FS, Firdaus
I, Philip PA, Cohn AL, Lewis N, Anderson DM, Arrowsmith E, Schwartz
JD, et al: Ramucirumab (RAM) plus FOLFOX as front-line therapy (Rx)
for advanced gastric or esophageal adenocarcinoma (GE-AC):
Randomized, double-blind, multicenter phase 2 trial. J Clin Oncol.
32(Suppl 5s): 40042014.
|
|
29
|
Bezjak A, Tu D, Seymour L, Clark G,
Trajkovic A, Zukin M, Ayoub J, Lago S, de Albuquerque Ribeiro R,
Gerogianni A, et al National Cancer Institute of Canada Clinical
Trials Group Study BR.21: Symptom improvement in lung cancer
patients treated with erlotinib: Quality of life analysis of the
National Cancer Institute of Canada Clinical Trials Group Study
BR.21. J Clin Oncol. 24:3831–3837. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Shepherd FA, Rodrigues Pereira J, Ciuleanu
T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S,
Smylie M, Martins R, et al National Cancer Institute of Canada
Clinical Trials Group: Erlotinib in previously treated
non-small-cell lung cancer. N Engl J Med. 353:123–132. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Motzer RJ, Hutson TE, Tomczak P,
Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik
C, Kim ST, et al: Sunitinib versus interferon alfa in metastatic
renal-cell carcinoma. N Engl J Med. 356:115–124. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Llovet JM, Ricci S, Mazzaferro V, Hilgard
P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A,
et al SHARP Investigators Study Group: Sorafenib in advanced
hepatocellular carcinoma. N Engl J Med. 359:378–390. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S,
Kim JS, Luo R, Feng J, Ye S, Yang TS, et al: Efficacy and safety of
sorafenib in patients in the Asia-Pacific region with advanced
hepatocellular carcinoma: A phase III randomised, double-blind,
placebo-controlled trial. Lancet Oncol. 10:25–34. 2009. View Article : Google Scholar
|
|
34
|
Martin-Richard M, Gallego R, Pericay C,
Garcia Foncillas J, Queralt B, Casado E, Barriuso J, Iranzo V, Juez
I, Visa L, et al: Multicenter phase II study of oxaliplatin and
sorafenib in advanced gastric adenocarcinoma after failure of
cisplatin and fluoropyrimidine treatment. A GEMCAD study. Invest
New Drugs. 31:1573–1579. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Sun W, Powell M, O'Dwyer PJ, Catalano P,
Ansari RH and Benson AB III: Phase II study of sorafenib in
combination with docetaxel and cisplatin in the treatment of
metastatic or advanced gastric and gastroesophageal junction
adenocarcinoma: ECOG 5203. J Clin Oncol. 28:2947–2951. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Bang YJ, Kang YK, Kang WK, Boku N, Chung
HC, Chen JS, Doi T, Sun Y, Shen L, Qin S, et al: Phase II study of
sunitinib as second-line treatment for advanced gastric cancer.
Invest New Drugs. 29:1449–1458. 2011. View Article : Google Scholar :
|
|
37
|
Boku N, Muro K, Machida N, Hashigaki S,
Kimura N, Suzuki M, Lechuga M and Miyata Y: Phase I study of
sunitinib plus S-1 and cisplatin in Japanese patients with advanced
or metastatic gastric cancer. Invest New Drugs. 32:261–270. 2014.
View Article : Google Scholar :
|
|
38
|
Lee KW, Park SR, Oh DY, Park YI, Khosravan
R, Lin X, Lee SY, Roh EJ, Valota O, Lechuga MJ, et al: Phase I
study of sunitinib plus capecitabine/cisplatin or
capecitabine/oxaliplatin in advanced gastric cancer. Invest New
Drugs. 31:1547–1558. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Li J, Qin S, Xu J, Guo W, Xiong J, Bai Y,
Sun G, Yang Y, Wang L, Xu N, et al: Apatinib for
chemotherapy-refractory advanced metastatic gastric cancer: Results
from a randomized, placebo-controlled, parallel-arm, phase II
trial. J Clin Oncol. 31:3219–3225. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Qin Sk; PLA Cancer Center of Nanjing Bayi
Hospital, Nanjing, China: Phrase III study of apatinib in advanced
gastric cancer: A randomized double-blind, placebo-controlled
trial. J Clin Oncol. 32(Suppl 5s): 40032014.
|
|
41
|
Satoh T, Xu RH, Chung HC, Sun GP, Doi T,
Xu JM, Tsuji A, Omuro Y, Li J, Wang JW, et al: Lapatinib plus
paclitaxel versus paclitaxel alone in the second-line treatment of
HER2-amplified advanced gastric cancer in Asian populations: TyTAN
- a randomized, phase III study. J Clin Oncol. 32:2039–2049. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
A Phase III study of ERBB2 positive
advanced or metastatic gastric or esophageal or gastroesophageal
junction adenocarcinoma treated with capecitabine plus oxaliplatin
with or without lapatinib. J Clin Oncol. 31(Suppl):
LBA40012013.
|
|
43
|
Oki E, Baba H, Tokunaga E, Nakamura T,
Ueda N, Futatsugi M, Mashino K, Yamamoto M, Ikebe M, Kakeji Y, et
al: Akt phosphorylation associates with LOH of PTEN and leads to
chemoresistance for gastric cancer. Int J Cancer. 117:376–380.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Lang SA, Gaumann A, Koehl GE, Seidel U,
Bataille F, Klein D, Ellis LM, Bolder U, Hofstaedter F, Schlitt HJ,
et al: Mammalian target of rapamycin is activated in human gastric
cancer and serves as a target for therapy in an experimental model.
Int J Cancer. 120:1803–1810. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Xu DZ, Geng QR, Tian Y, Cai MY, Fang XJ,
Zhan YQ, Zhou ZW, Li W, Chen YB, Sun XW, et al: Activated mammalian
target of rapamycin is a potential therapeutic target in gastric
cancer. BMC Cancer. 10:5362010. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Yu G, Wang J, Chen Y, Wang X, Pan J, Li G,
Jia Z, Li Q, Yao JC and Xie K: Overexpression of phosphorylated
mammalian target of rapamycin predicts lymph node metastasis and
prognosis of Chinese patients with gastric cancer. Clin Cancer Res.
15:1821–1829. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
An JY, Kim KM, Choi MG, Noh JH, Sohn TS,
Bae JM and Kim S: Prognostic role of p-mTOR expression in cancer
tissues and metastatic lymph nodes in pT2b gastric cancer. Int J
Cancer. 126:2904–2913. 2010.
|
|
48
|
Wan X and Helman LJ: The biology behind
mTOR inhibition in sarcoma. Oncologist. 12:1007–1018. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Lim T, Lee J, Lee DJ, Lee HY, Han B, Baek
KK, Ahn HK, Lee SJ, Park SH, Park JO, et al: Phase I trial of
capecitabine plus everolimus (RAD001) in patients with previously
treated metastatic gastric cancer. Cancer Chemother Pharmacol.
68:255–262. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Doi T, Muro K, Boku N, Yamada Y, Nishina
T, Takiuchi H, Komatsu Y, Hamamoto Y, Ohno N, Fujita Y, et al:
Multicenter phase II study of everolimus in patients with
previously treated metastatic gastric cancer. J Clin Oncol.
28:1904–1910. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Ohtsu A, Ajani JA, Bai YX, Bang YJ, Chung
HC, Pan HM, Sahmoud T, Shen L, Yeh KH, Chin K, et al: Everolimus
for previously treated advanced gastric cancer: Results of the
randomized, double-blind, phase III GRANITE-1 study. J Clin Oncol.
31:13935–13943. 2013. View Article : Google Scholar
|
|
52
|
Slørdahl TS, Denayer T, Moen SH, Standal
T, Børset M, Ververken C and Rø TB: Anti-c-MET nanobody - a new
potential drug in multiple myeloma treatment. Eur J Haematol.
91:399–410. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Stellrecht CM and Gandhi V: MET receptor
tyrosine kinase as a therapeutic anticancer target. Cancer Lett.
280:1–14. 2009. View Article : Google Scholar
|
|
54
|
Sotoudeh K, Hashemi F, Madjd Z,
Sadeghipour A, Molanaei S and Kalantary E: The clinicopathologic
association of c-MET overexpression in Iranian gastric carcinomas;
an immunohistochemical study of tissue microarrays. Diagn Pathol.
7:572012. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Ha SY, Lee J, Kang SY, Do IG, Ahn S, Park
JO, Kang WK, Choi MG, Sohn TS, Bae JM, et al: MET overexpression
assessed by new interpretation method predicts gene amplification
and poor survival in advanced gastric carcinomas. Mod Pathol.
26:1632–1641. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Fuse N, Kuboki Y, Kuwata T, Nishina T,
Kadowaki S, Shinozaki E, Machida N, Yuki S, Ooki A, Kajiura S, et
al: Prognostic impact of HER2, EGFR, and c-MET status on overall
survival of advanced gastric cancer patients. Gastric Cancer. Feb
15–2015.Epub ahead of print. PubMed/NCBI
|
|
57
|
Iveson T, Donehower RC, Davidenko I,
Tjulandin S, Deptala A, Harrison M, Nirni S, Lakshmaiah K, Thomas
A, Jiang Y, et al: Rilotumumab in combination with epirubicin,
cisplatin, and capecitabine as first-line treatment for gastric or
oesophagogastric junction adenocarcinoma: An open-label, dose
de-escalation phase 1b study and a double-blind, randomised phase 2
study. Lancet Oncol. 15:1007–1018. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Shah MA, Cho JY, Huat ITB, Tebbutt NC, Yen
CJ, Kang A, Shames DS, Bu L and Kang YK: Randomized phase II study
of FOLFOX/- MET inhibitor, onartuzumab (O), in advanced
gastroesophageal adenocarcinoma (GEC). J Clin Oncol. 33:abstract 2.
2015.
|
|
59
|
Bang YJ, Im SA, Lee KW, Cho JY, Song EK,
Lee KH, Kim YH, Park JO, Chun HG, Zang DY, et al: Randomized,
double-blind phase II trial with prospective classification by ATM
protein level to evaluate the efficacy and tolerability of olaparib
plus paclitaxel in patients with recurrent or metastatic gastric
cancer. J Clin Oncol. 33:3858–3865. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Malenfant SJ, Eckmann KR and Barnett CM:
Pertuzumab: A new targeted therapy for HER2-positive metastatic
breast cancer. Pharmacotherapy. 34:60–71. 2014. View Article : Google Scholar
|
|
61
|
Baselga J, Cortés J, Kim SB, Im SA, Hegg
R, Im YH, Roman L, Pedrini JL, Pienkowski T, Knott A, et al
CLEOPATRA Study Group: Pertuzumab plus trastuzumab plus docetaxel
for metastatic breast cancer. N Engl J Med. 366:109–119. 2012.
View Article : Google Scholar
|
|
62
|
Swain SM, Baselga J, Kim SB, Ro J,
Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneeweiss A,
Heeson S, et al CLEOPATRA Study Group: Pertuzumab, trastuzumab, and
docetaxel in HER2-positive metastatic breast cancer. N Engl J Med.
372:724–734. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Kang YK, Rha SY, Tassone P, Barriuso J, Yu
R, Szado T, Garg A and Bang YJ: A phase IIa dose-finding and safety
study of first-line pertuzumab in combination with trastuzumab,
capecitabine and cisplatin in patients with HER2-positive advanced
gastric cancer. Br J Cancer. 111:660–666. 2014. View Article : Google Scholar : PubMed/NCBI
|
